CITROclorex 2% RED

CITROclorex 2% RED

Ready to use skin disinfection solution with dye.

Based on 70% (w/w) Ethanol and 2% (w/w) Chlorhexidine digluconate, CITROclorex 2% RED allows excellent marking of the skin area to be disinfected prior to surgical procedures (for example in surgeries).

product DETAILS

Unlike other chlorhexidine based products, CITROclorex 2% RED’s particular dying agent ensures a persistent red colour on the skin area to be treated.

It also provides:

◢ Broad spectrum efficacy
◢ Good skin compatibility – contains glycerine
◢ Immediate and residual efficacy 
◢ Ease of use

Our performance Your advantage
Unique CITROclorex 2% RED is the only permanent staining solution based on chlorhexidine digluconate. Consequently it helps reduce preparation time and effort prior to surgery.
Efficacy assured Being based on the active ingredients of 2% (w/w) chlorhexidine digluconate and 70% (w/w) ethanol, a broad spectrum of efficacy is assured against bacteria (incl. tuberculocidal efficacy), yeast, enveloped viruses (incl. HBV, HCV and HIV according to RKI 01/2004).
Sustained effect Additionally to its immediate antimicrobial effect, chlorhexidine digluconate provides provides a prolonged effect after product application.
Tested and validated Many international guidelines confirm the use of chlorhexidine gluconate-based products for skin disinfection. The table below outlines a selection of publications on the subject.


100g of product contain (w/w):

Active substances: 2g Chlorhexidine digluconate, 70g Ethanol. Excipients: dye, glycerine, purified water up to 100g.

Use biocide products with caution. Always read the label and product information before use.

Related Offerings

Please see below related offerings:

This is a carousel. Use Next and Previous buttons to navigate, or jump to a slide with the slide dots.


For more product details, pack sizes and all relevant order codes, please download the product brochure below.



Ecolab Healthcare can partner with you to help increase efficiency, improve outcomes and reduce the risk of Healthcare Associated Infections (HAIs).